Correlation Between Vascular Endothelial Growth Factor and Long-Term Occurrence of HCV-Related Hepatocellular Carcinoma After Treatment with Direct-Acting Antivirals

References

• Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538. doi:10.1016/j.jhep.2006.05.013.
   PubMed Web of Science ®Google Scholar
• Zahran AM, Hetta HF, Rayan A, Eldin AS, Hassan EA, Fakhry H, et al. Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes. Cancer Immunol Immunother. 2020;69(7):1211–1253. doi:10.1007/s00262-019-02465-y.
   Web of Science ®Google Scholar
• Abd El-Baky RM, Hetta HF, Koneru G, Ammar M, Shafik EA, Mohareb DA, et al. Impact of interleukin IL-6 rs-1474347 and IL-10 rs-1800896 genetic polymorphisms on the susceptibility of HCV-infected Egyptian patients to hepatocellular carcinoma. Immunol Res. 2020;68(3):118–125. doi:10.1007/s12026-020-09126-8.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2001;5(1):87–107. doi:10.1016/S1089-3261(05)70155-0.
   PubMedGoogle Scholar
• Abouelezz K, Khanapara D, Batiha GE-S, Ahmed EA, Hetta HF. Cytotoxic chemotherapy as an alternative for systemic treatment of advanced hepatocellular carcinoma in developing countries. Cancer Manag Res. 2020;12:12239–12248. doi:10.2147/CMAR.S280631.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Abubakar I, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171.
   PubMed Web of Science ®Google Scholar
• Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology. 2018;155(2): 411–421.e4. doi:10.1053/j.gastro.2018.04.008.
   PubMed Web of Science ®Google Scholar
• Abd Ellah NH, Tawfeek HM, John J, Hetta HF. Nanomedicine as a future therapeutic approach for Hepatitis C virus. Nanomedicine (Lond). 2019;14(11):1471–1491. doi:10.2217/nnm-2018-0348.
   PubMed Web of Science ®Google Scholar
• Hetta HF, Zahran AM, Mansor SG, Abdel‐Malek MO, Mekky MA, Abbas WA. Frequency and implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. J Med Virol. 2019;91(7):1319–1328. doi:10.1002/jmv.25428.
   PubMed Web of Science ®Google Scholar
• Mekky MA, Sayed HI, Abdelmalek MO, Saleh MA, Osman OA, Osman HA, et al. Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study. Infect Drug Resist. 2019;12:273–279. doi:10.2147/IDR.S181638.
   PubMed Web of Science ®Google Scholar
• Abdel-Hameed EA, Rouster SD, Ji H, Ulm A, Hetta HF, Anwar N, et al. Evaluating the role of cellular immune responses in the emergence of HCV NS3 resistance mutations during protease inhibitor therapy. Viral Immunol. 2016;29(4):252–258. doi:10.1089/vim.2015.0093.
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–733. doi:10.1016/j.jhep.2016.06.015.
   PubMed Web of Science ®Google Scholar
• Zavaglia C, Okolicsanyi S, Cesarini L, Mazzarelli C, Pontecorvi V, Ciaccio A, et al. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol. 2017;66(1):236–237. doi:10.1016/j.jhep.2016.08.016.
   PubMed Web of Science ®Google Scholar
• Minami T, Tateishi R, Nakagomi R, Fujiwara N, Sato M, Enooku K, et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol. 2016;65(6):1272–1273. doi:10.1016/j.jhep.2016.07.043.
   PubMed Web of Science ®Google Scholar
• Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719–726. doi:10.1016/j.jhep.2016.04.008.
   PubMed Web of Science ®Google Scholar
• Nault J-C, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol. 2016;65(4):663–665. doi:10.1016/j.jhep.2016.07.004.
   PubMed Web of Science ®Google Scholar
• Sayed HAR, Hetta HF, Shafik EA, Zahran AM. Flow cytometric analysis of circulating endothelial cells and endothelial progenitor cells in pediatric solid tumors: prognostic impact on treatment response and survival. Cancer Immunol Immunother. 2021;70(3):755–761. doi:10.1007/s00262-020-02719-0.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al.; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35(3):421–430. doi:10.1016/S0168-8278(01)00130-1.
   PubMed Web of Science ®Google Scholar
• Bhattacharya R, Sinha S, Yang S-P, Patra C, Dutta S, Wang E, et al. The neurotransmitter dopamine modulates vascular permeability in the endothelium. J Mol Signal. 2008;3:14. doi:10.1186/1750-2187-3-14.
   PubMedGoogle Scholar
• Kaumaya PT, Foy KC. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol. 2012;8(8):961–987. doi:10.2217/fon.12.95.
   PubMed Web of Science ®Google Scholar
• Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell. 2010;140(2):268–279. doi:10.1016/j.cell.2009.12.046.
   PubMed Web of Science ®Google Scholar
• Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2005;65(9):3691–3699. doi:10.1158/0008-5472.CAN-04-3462.
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, et al. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut. 2005;54(12):1768–1775. doi:10.1136/gut.2005.067900.
   PubMed Web of Science ®Google Scholar
• Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, Landriscina M, et al. DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment. PLoS One. 2016;11(12):e0167934. doi:10.1371/journal.pone.0167934.
   PubMed Web of Science ®Google Scholar
• Faillaci F, Marzi L, Critelli R, Milosa F, Schepis F, Turola E, et al. Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals. Hepatology. 2018;68(3):1010–1024. doi:10.1002/hep.29911.
   PubMed Web of Science ®Google Scholar
• Hetta HF, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, et al. Association of colonic regulatory T cells with hepatitis C virus pathogenesis and liver pathology. J Gastroenterol Hepatol. 2015;30(10):1543–1551. doi:10.1111/jgh.12936.
   PubMed Web of Science ®Google Scholar
• Hetta HF, Mehta MJ, Shata MTM. Gut immune response in the presence of hepatitis C virus infection. WJI. 2014;4(2):52–62. doi:10.5411/wji.v4.i2.52.
   Google Scholar
• Shata MTM, Abdel-Hameed EA, Hetta HF, Sherman KE. Immune activation in HIV/HCV-infected patients is associated with low-level expression of liver expressed antimicrobial peptide-2 (LEAP-2). J Clin Pathol. 2013;66(11):967–975. doi:10.1136/jclinpath-2013-201581.
   PubMedGoogle Scholar
• Mehta M, Hetta HF, Abdel-Hameed EA, Rouster SD, Hossain M, Mekky MA, et al. Association between IL28b rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. Arch Virol. 2016;161(11):3161–3169. doi:10.1007/s00705-016-3015-4.
   PubMed Web of Science ®Google Scholar
• Abdelwahab FA, Hassanein KM, Hetta HF, Abdelmalek MO, Zahran AM, El-Badawy O. Impact of deranged B cell subsets distribution in the development of HCV-related cirrhosis and HCC in type two diabetes mellitus. Sci Rep. 2020;10(1):11. doi:10.1038/s41598-020-77416-0.
   PubMed Web of Science ®Google Scholar
• Zahran AM, Nafady-Hego H, Mansor SG, Abbas WA, Abdel-Malek MO, Mekky MA, et al. Increased frequency and FOXP3 expression of human CD8+ CD25High + T lymphocytes and its relation to CD4 regulatory T cells in patients with hepatocellular carcinoma. Hum Immunol. 2019;80(7):510–516. doi:10.1016/j.humimm.2019.03.014.
   PubMed Web of Science ®Google Scholar
• Zahran AM, Zahran ZAM, El-Badawy O, Abdel-Rahim MH, Ali WAM, Rayan A, et al. Prognostic impact of toll-like receptors 2 and 4 expression on monocytes in Egyptian patients with hepatocellular carcinoma. Immunol Res. 2019;67(2–3):157–165. doi:10.1007/s12026-019-09075-x.
   PubMed Web of Science ®Google Scholar
• Hetta HF, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, et al. Extra-hepatic infection of hepatitis C virus in the colon tissue and its relationship with hepatitis C virus pathogenesis. J Med Microbiol. 2016;65(8):703–712. doi:10.1099/jmm.0.000272.
   PubMed Web of Science ®Google Scholar
• Hassan M, Selimovic D, El-Khattouti A, Soell M, Ghozlan H, Haikel Y, et al. Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies. World J Gastroenterol. 2014;20(42):15467–15475. doi:10.3748/wjg.v20.i42.15467.
   PubMed Web of Science ®Google Scholar
• Hassan EA, Ahmed EH, Nafee AM, El-Gafary N, Hetta HF, El-Mokhtar MA. Regulatory T cells, IL10 and IL6 in HCV related hepatocellular carcinoma after transarterial chemoembolization (TACE). Egypt J Immunol. 2019;26:69–78.
   PubMedGoogle Scholar
• Zahran AM, Ashmawy AM, Rayan A, Elkady A, Elsherbiny NM, Hetta HF. Frequency and implications of natural killer and natural killer T cells in hepatocellular carcinoma. Egypt J Immunol. 2018;25:45–52.
   PubMedGoogle Scholar
• Hetta H, Elkady A, Morsy K, Mohamed I, Ibrahim M. Serum level of IL17a among cirrhotic hepatitis C virus infected patients with incidence of diabetes mellitus. Egypt J Immunol. 2017;24:79.
   PubMedGoogle Scholar
• Hetta HF, Khairy H, Ismail S. Circulating IL17A and IFN-gamma serum levels in cirrhotic hepatitis C virus infected patients with autoimmune thyroiditis. Int J Curr Microbiol Appl Sci. 2017;6:1972–1983.
   Google Scholar
• Hetta H, Elkady A, Tohamy T, Badary M. Regulatory B cells: key players in hepatocellular carcinoma progression. Gastroenterol Hepatol Open Access. 2016;5:00136.
   Google Scholar
• Tandle A, Blazer DG, Libutti SK. Antiangiogenic gene therapy of cancer: recent developments. J Transl Med. 2004;2(1):22. doi:10.1186/1479-5876-2-22.
   PubMedGoogle Scholar
• Hassan M, Selimovic D, Ghozlan H, Abdel‐Kader O. Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology. 2009;49(5):1469–1482. doi:10.1002/hep.22849.
   PubMed Web of Science ®Google Scholar
• Salcedo X, Medina J, Sanz-Cameno P, García-Buey L, Martín-Vilchez S, Borque MJ, et al. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology. 2005;42(3):696–701. doi:10.1002/hep.20828.
   PubMed Web of Science ®Google Scholar
• Chaturvedi VK, Singh A, Dubey SK, Hetta HF, John J, Singh M. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma. Microb Pathog. 2019;128:184–194. doi:10.1016/j.micpath.2019.01.004.
   PubMed Web of Science ®Google Scholar
• Bupathi M, Kaseb A, Janku F. Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives. Onco Targets Ther. 2014;7:1927–1932. doi:10.2147/OTT.S46457.
   PubMed Web of Science ®Google Scholar
• Torimura T, Ueno T, Kin M, Harada R, Taniguchi E, Nakamura T, et al. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol. 2004;40(5):799–807. doi:10.1016/j.jhep.2004.01.027.
   PubMed Web of Science ®Google Scholar
• Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J. 1999;13(1):9–22.
   PubMed Web of Science ®Google Scholar
• Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology. 1996;23(3):455–464. doi:10.1002/hep.510230309.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Horbach A, Kubitz R, Frilling A, Häussinger D. Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol. 2004;41(2):274–283. doi:10.1016/j.jhep.2004.04.035.
   PubMed Web of Science ®Google Scholar
• Park YN, Kim Y-B, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med. 2000;124(7):1061–1065. doi:10.5858/2000-124-1061-IEOVEG.
   PubMed Web of Science ®Google Scholar
• Wang C-C, Tseng K-C, Tzeng I-S, Kao J-H. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma. J Formos Med Assoc. 2021;120(3):965–973. doi:10.1016/j.jfma.2020.10.015.
   PubMed Web of Science ®Google Scholar
• Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, von Felden J, et al. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology. 2018;154(3):515–517. e3. doi:10.1053/j.gastro.2017.10.035.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8(5):292–301. doi:10.1038/nrclinonc.2011.30.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676. doi:10.1038/nm0603-669.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El‐Serag HB. Long‐term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology. 2020;71(1):44–55. doi:10.1002/hep.30823.
   PubMed Web of Science ®Google Scholar